457 related articles for article (PubMed ID: 35620395)
1. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
Wang Y; Huang Z; Li B; Liu L; Huang C
Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Borley J; Brown R
Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
Zhang Q; Ding J; Wang Y; He L; Xue F
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35362546
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in ovarian cancer: from mechanism to clinical trial.
Wang L; Wang X; Zhu X; Zhong L; Jiang Q; Wang Y; Tang Q; Li Q; Zhang C; Wang H; Zou D
Mol Cancer; 2024 Mar; 23(1):66. PubMed ID: 38539161
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
Greville G; McCann A; Rudd PM; Saldova R
Epigenetics; 2016 Dec; 11(12):845-857. PubMed ID: 27689695
[TBL] [Abstract][Full Text] [Related]
8. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
Matei D; Nephew KP
Cancer Res; 2020 Sep; 80(18):3775-3785. PubMed ID: 32381656
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
[TBL] [Abstract][Full Text] [Related]
12. Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
Rubatto M; Borriello S; Sciamarrelli N; Pala V; Tonella L; Ribero S; Quaglino P
Melanoma Res; 2023 Dec; 33(6):462-474. PubMed ID: 37788101
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives.
Papakonstantinou E; Androutsopoulos G; Logotheti S; Adonakis G; Maroulis I; Tzelepi V
Curr Mol Pharmacol; 2021; 14(6):1013-1027. PubMed ID: 32778046
[TBL] [Abstract][Full Text] [Related]
14. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Sriramkumar S; Metcalfe TX; Lai T; Zong X; Fang F; O'Hagan HM; Nephew KP
PLoS One; 2022; 17(8):e0271584. PubMed ID: 35921335
[TBL] [Abstract][Full Text] [Related]
15. Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer.
Yan B; Xiong C; Huang F; Zhang M; Mo Y; Bai H
Medicine (Baltimore); 2020 Jul; 99(27):e20802. PubMed ID: 32629664
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer: epigenetics, drug resistance, and progression.
Xie W; Sun H; Li X; Lin F; Wang Z; Wang X
Cancer Cell Int; 2021 Aug; 21(1):434. PubMed ID: 34404407
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer-associated genes in ovarian cancer.
Kwon MJ; Shin YK
Int J Mol Sci; 2011 Jan; 12(2):983-1008. PubMed ID: 21541038
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
20. RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges.
Ye L; Yao X; Xu B; Chen W; Lou H; Tong X; Fang S; Zou R; Hu Y; Wang Z; Xiang D; Lin Q; Feng S; Xue X; Guo G
Wiley Interdiscip Rev RNA; 2023; 14(5):e1784. PubMed ID: 36811232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
